Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.

Abstract

The introduction of targeted therapies, specifically those that target the VEGF receptor (VEGFR), PDGF receptor (PDGFR) and the mTOR pathways, has significantly changed the approach to patients with unresectable renal cell cancer (RCC). However, drug resistance develops through bypassing of targeted pathways. Regorafenib (BAY 73-4506) is a novel bi-aryl… (More)
DOI: 10.1007/s11912-013-0292-x

Topics

2 Figures and Tables

Cite this paper

@article{Zaki2013Regorafenib7, title={Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.}, author={Kamarul Ahmad Zaki and Shahzeena Aslam and Tim G Eisen}, journal={Current oncology reports}, year={2013}, volume={15 2}, pages={91-7} }